Avadel Pharmaceuticals

Avadel Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Wednesday, May 18, 2022
Cataplexy, Patient, Sodium oxybate, Somnolence, Narcolepsy, Conference, Nasdaq, GLOBE, Pharmaceutical industry, Avadel Pharmaceuticals

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.

Key Points: 
  • DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25 at 8:30 a.m. E.T.
  • A live webcast of the fireside chat, as well as an archived recording, will be available on Avadels Investor Relations website, investors.avadel.com , for 90 days following the conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.
  • Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.

Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results

Retrieved on: 
Monday, May 9, 2022
CNS Drugs (journal), REM, U.S. Securities and Exchange Commission, Sleep, Narcolepsy, Forward-looking statement, World, Nasdaq, EDS, GLOBE, Company, Medicine, NDA, Excessive daytime sleepiness, Securities Act of 1933, Securities Exchange Act of 1934, Food, Injury, Safety, AAN, Patient, Security (finance), Review, Webcast, FDA, International, Drug Quality and Security Act, Anxiety, Avadel Pharmaceuticals, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Knowledge, New Drug Application, Income, American Academy, Cataplexy, SEC, ID, Research, Sodium oxybate, Pharmaceutical industry, Fine chemical, Risk management, Video game

ET

Key Points: 
  • ET
    DUBLIN, Ireland, May 09, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update, and announced its financial results for the first quarter ended March 31, 2022.
  • R&D expenses were $7.0 million in the quarter ended March 31, 2022, compared to $3.9 million for the same period in 2021.
  • SG&A expenses were $21.6 million in the quarter ended March 31, 2022, compared to $11.0 million for the same period in 2021.
  • The Company does not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Avadel Pharmaceuticals Provides Comment on Recent Trading Activity

Retrieved on: 
Tuesday, April 26, 2022
Sodium oxybate, NDA, Avadel Pharmaceuticals, U.S. Securities and Exchange Commission, Security (finance), Regulation of tobacco by the U.S. Food and Drug Administration, Excessive daytime sleepiness, Food, GLOBE, Drug Quality and Security Act, Patient, Cataplexy, Securities Exchange Act of 1934, Review, Nasdaq, Company, Movement, SEC, Forward-looking statement, Narcolepsy, Safety, FDA, Securities Act of 1933, Knowledge, EDS, Pharmaceutical industry

DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a statement in response to the trading volatility and subsequent brief trading halt of its shares that occurred yesterday.

Key Points: 
  • DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a statement in response to the trading volatility and subsequent brief trading halt of its shares that occurred yesterday.
  • The company is not aware of any new information, including regarding the ongoing review of the FT218 NDA, that caused yesterdays share price movement and brief trading halt, said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals.
  • In March 2020, Avadel completed the REST-ON study, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial, to assess the efficacy and safety of FT218 in patients with narcolepsy.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.

Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting

Retrieved on: 
Monday, April 25, 2022
Sodium oxybate, Injury, Sleep, U.S. Securities and Exchange Commission, Security (finance), Annual report, Excessive daytime sleepiness, Hypnagogia, Anxiety, GLOBE, Drug Quality and Security Act, Cataplexy, Patient, Securities Exchange Act of 1934, Review, EDS, Medical director, Nasdaq, SEC, Forward-looking statement, Sleep paralysis, AAN, Narcolepsy, Safety, American Academy, FDA, Securities Act of 1933, Knowledge, DNS, Pharmaceutical industry, Risk management, Avadel Pharmaceuticals

DUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022.

Key Points: 
  • DUBLIN, Ireland, April 25, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the presentation of interim data from the ongoing RESTORE open-label extension/switch study of FT218 at the 2022 American Academy of Neurology Annual (AAN) Meeting being held virtually from April 24-26, 2022.
  • Results from the questionnaire follow:
    Out of 60 participants, 38 (63%) unintentionally missed their second twice-nightly oxybate dose within the preceding three months.
  • Avadel is currently evaluating the long-term safety and tolerability of FT218 in the open-label RESTORE clinical study.
  • We do not undertake any obligation to publicly update or revise our forward-looking statements, except as required by law.

Avadel Pharmaceuticals to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, March 22, 2022
GLOBE, Cataplexy, Narcolepsy, Conference, Sodium oxybate, Somnolence, Patient, Nasdaq, Pharmaceutical industry, Avadel Pharmaceuticals

DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:

Key Points: 
  • DUBLIN, Ireland, March 22, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
    Stifel 2022 Virtual CNS Day: Fireside chat on Tuesday, March 29 at 12:00 p.m. E.T.
  • 21st Annual Needham Virtual Healthcare Conference: Fireside chat on Monday, April 11 at 2:15 p.m. E.T.
  • Live webcast of these events, as well as archived recordings, will be available on Avadels Investor Relations website, investors.avadel.com , for 90 days following each conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.

Avadel Pharmaceuticals Announces Appointment of Brandi Robinson as Senior Vice President, Corporate Affairs

Retrieved on: 
Monday, March 14, 2022
Executive Committee, Cataplexy, Journalism, SEC, Employment, Public relations, Seagen, GLOBE, Novartis, Narcolepsy, Patient, Therapy, Nasdaq, Knowledge, Sodium oxybate, Senior, Forward-looking statement, Financial compensation, Security (finance), Board, Somnolence, Mallinckrodt, Company, Cancer, American depositary receipt, Corporate Affairs, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Securities Act of 1933, S-1 Executive Committee, Fairleigh Dickinson University, Sanofi, Management, Pharmaceutical industry, Risk management, Communication, Avadel Pharmaceuticals

DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs.

Key Points: 
  • DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs.
  • Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the company as we expand.
  • Its an exciting time to join Avadel, as the Company continues to build operational capabilities for the potential launch of FT218, said Brandi Robinson.
  • At Rafael Holdings, Brandi led the communications, corporate affairs and patient advocacy functions, and served as a member of the Executive Committee.

NATIONAL SLEEP FOUNDATION'S 2022 SLEEP IN AMERICA® POLL: Americans Can Do More During the Day and Night to Improve Sleep

Retrieved on: 
Monday, March 14, 2022
List of minor secular observances, Awareness, National Sleep Foundation, Exercise, Avadel Pharmaceuticals, Jazz Pharmaceuticals, Research, Associate, Sleep, Poll, Health, CDC, NSF, Meal, Habit, CEO, Pharmaceutical industry, Medicine

WASHINGTON, March 14, 2022 /PRNewswire/ --To kick off their Sleep Awareness Week , National Sleep Foundation released the latest results from the 2022 Sleep in America Poll .

Key Points: 
  • WASHINGTON, March 14, 2022 /PRNewswire/ --To kick off their Sleep Awareness Week , National Sleep Foundation released the latest results from the 2022 Sleep in America Poll .
  • The 2022 Sleep in America Poll documents significant opportunities to improve daily activities that are associated with a range of positive sleep and health outcomes.
  • "Over the last 31 years, the National Sleep Foundation has conducted the Sleep in America Poll to gain a better understanding of Americans' sleep health and habits.
  • The Sleep in America Poll is fielded annually and results are shared during National Sleep Foundation's Sleep Awareness Week.

Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022

Retrieved on: 
Friday, March 11, 2022
Nasdaq, Safety, Drug Quality and Security Act, Securities Act of 1933, Congress, Sodium oxybate, Developmental Medicine & Child Neurology, Sleep medicine, U.S. Securities and Exchange Commission, FDA, Â, Cataplexy, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sleep, Quality of life, Neurology, Narcolepsy, Securities Exchange Act of 1934, Medicine, Forward-looking statement, Excessive daytime sleepiness, Geisinger Medical Center, Hypnagogia, GLOBE, Patient, Security (finance), 2021 Essex County Council election, Solution, Sleep paralysis, Knowledge, World Sleep Day, Somnolence, DCE, SEC, Food, Review, EDS, Pharmaceutical industry, Dietary supplement, Risk management, Child, Avadel Pharmaceuticals

New post-hoc data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and interim data from the ongoing RESTORE open-label extension/switch study of FT218 will also be presented.

Key Points: 
  • New post-hoc data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and interim data from the ongoing RESTORE open-label extension/switch study of FT218 will also be presented.
  • We know that untreated narcolepsy can have a devastating effect on patients quality of life and ability to function and that additional treatment options would benefit patients and clinicians.
  • All accepted abstracts are available on the World Sleep Congress website and will be published in an upcoming Sleep Medicine journal supplement.
  • At Avadel, we believe in listening to patients to develop solutions that will have a meaningful impact on their symptoms.

Avadel Pharmaceuticals to Present at the Oppenheimer 32nd Annual Healthcare Conference

Retrieved on: 
Thursday, March 10, 2022
Cataplexy, Nasdaq, Somnolence, Narcolepsy, GLOBE, Conference, Patient, Sodium oxybate, Pharmaceutical industry, Avadel Pharmaceuticals

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m.

Key Points: 
  • DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at the Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17 at 10:40 a.m.
  • A live webcast of the fireside chat, as well as an archived recording, will be available on Avadels Investor Relations website, investors.avadel.com , for 90 days following the conference.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.
  • Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options.

Avadel to Present New Clinical Data at World Sleep 2022

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Geisinger Medical Center, Provider, Narcolepsy, Regulation of tobacco by the U.S. Food and Drug Administration, Stanford University Medical Center, Time, Cataplexy, Poster, Stanford University, Department, International Chinese Language Program, Excessive daytime sleepiness, Discrete, Somnolence, Psychiatry, Company, World, Safety, College of Arts and Sciences, Avadel Pharmaceuticals, Neurology, Child, Sleep paralysis, Review, Food, Gamma-Hydroxybutyric acid, Albert Einstein College of Medicine, EDS, FDA, Nasdaq, Patient, Developmental Medicine & Child Neurology, Sodium oxybate, Hypnagogia, Sleep, Montefiore, CET, Gui, Department of Neurology, Xuanwu hospital, Pharmaceutical industry, Communications satellite, Online gambling, Antibiotics

DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present eight posters at World Sleep 2022, taking place March 11-16 in Rome, Italy.

Key Points: 
  • DUBLIN, Ireland, March 01, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present eight posters at World Sleep 2022, taking place March 11-16 in Rome, Italy.
  • The presentations will feature new data from the completed pivotal Phase 3 REST-ON clinical trial of FT218 and the ongoing RESTORE open-label extension/switch study of FT218.
  • Additional symptoms can vary by person and may include disrupted nighttime sleep, a sudden loss of muscle tone usually triggered by strong emotion (cataplexy), sleep paralysis and hypnagogic hallucinations.
  • Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives.